Literature DB >> 1384376

Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin's disease. Mediation by Epstein-Barr virus.

H Momose1, E S Jaffe, S S Shin, Y Y Chen, L M Weiss.   

Abstract

The pathogenesis of Reed-Sternberg cells and variants (RS-H cells) found in rare cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is unknown. We studied 13 such cases by immunohistochemistry and in situ hybridization for identification of Epstein-Barr virus (EBV) RNA. The RS-H cells in five cases expressed the B-lineage marker CD20 and were negative for CD15. In two cases, the RS-H cells showed expression of both CD20 and CD15, whereas in another six cases, the cells were positive for CD15 but negative for CD20. Three of the cases expressing CD15 showed subsequent evidence of disseminated Hodgkin's disease. Regardless of the phenotype or clinical behavior, the RS-H cells in 12 of 13 cases were found to contain EBV RNA by in situ hybridization, but the surrounding neoplastic lymphocytes were invariably negative for EBV RNA. It is suggested that EBV has an important role in the pathogenesis of the RS-H cells in these rare cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384376     DOI: 10.1097/00000478-199209000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia.

Authors:  A Miyata; K Kojima; T Yoshino; S Fujii; K Shinagawa; K Ichimura
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

Review 2.  Richter's transformation in chronic lymphocytic leukemia.

Authors:  Apostolia-Maria Tsimberidou; Michael J Keating; William G Wierda
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

Review 3.  Recent advances in the diagnosis and therapy of Richter's syndrome.

Authors:  Ronan Swords; John Bruzzi; Francis Giles
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor?

Authors:  Riccardo Dolcetti; Antonino Carbone
Journal:  Infect Agent Cancer       Date:  2010-11-22       Impact factor: 2.965

5.  Transformation of follicular lymphoma to Epstein-Barr virus-related Hodgkin-like lymphoma.

Authors:  Madhu P Menon; Lloyd Hutchinson; Joanne Garver; Elaine S Jaffe; Bruce A Woda
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

Review 6.  Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.

Authors:  Scott D Boyd; Yasodha Natkunam; John R Allen; Roger A Warnke
Journal:  Appl Immunohistochem Mol Morphol       Date:  2013-03

7.  Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.

Authors:  Sameer A Parikh; Thomas M Habermann; Kari G Chaffee; Timothy G Call; Wei Ding; Jose F Leis; William R Macon; Susan M Schwager; Kay M Ristow; Luis F Porrata; Neil E Kay; Susan L Slager; Tait D Shanafelt
Journal:  Am J Hematol       Date:  2015-01-30       Impact factor: 10.047

8.  Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  John R Krause; Lee C Drinkard; Latoya C Keglovits
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-01

Review 9.  Relationship between Hodgkin's and non-Hodgkin's lymphomas.

Authors:  Rose-Marie Amini; Gunilla Enblad
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

10.  Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist.

Authors:  Alina Nicolae; Stefania Pittaluga; Girish Venkataraman; Anahi Vijnovich-Baron; Liqiang Xi; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2013-06       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.